PT-141 for Women: the HSDD Indication in the Research

The short version

PT-141 for women is the only use that carries an FDA approval — and even then, only some women. Bremelanotide is approved for acquired, generalized HSDD (hypoactive sexual desire disorder — persistent low sexual desire that causes real personal distress) in premenopausal women, full stop ^[6]. In the big trials it raised desire and eased the distress around it; a brain scan showed it working centrally, in wiring, for up to a day ^[3][5]. The catch: the effect was modest, and about four in ten people on it long-term felt nauseated ^[4]. Postmenopausal women are outside the approval. So is every man.

Is PT-141 FDA-approved?

Yes — narrowly. Bremelanotide is FDA-approved (NDA 210557, June 21, 2019) as a subcutaneous injection for acquired, generalized HSDD in premenopausal women ^[6]. That is the whole approval. It is not approved for men, for postmenopausal women, for erectile dysfunction, or for sexual 'performance' of any kind ^[6].

The distinction that trips people up: 'PT-141 research chemical' is the same molecule sold for laboratory use only and sits entirely outside this approval — no regulatory oversight of identity, purity, or concentration ^[6]. Approved drug and research chemical are the same compound on paper and very different things in practice.

Where the female indication came from

It did not start in women — it started in female rats, and that origin is worth knowing because it shaped what the human trials looked for. A 2004 study reported that a melanocortin receptor agonist selectively increased solicitational (desire-driven, proceptive) sexual behaviour in female rats without changing reflexive behaviour, pacing, or general movement ^[2]. It was described as the first pharmacological agent acting specifically on appetitive female sexual behaviour ^[2].

That is a precise finding: the molecule moved desire, not mechanics. The human program inherited that framing, which is why the Phase 3 co-primary endpoints measured desire and the distress around it rather than arousal plumbing ^[3]. The animal-to-human thread is unusually clean here — desire-selective behaviour in rats, a desire-and-distress endpoint in women — and it is part of why the approved indication is specifically a desire disorder.

What does PT-141 do for women?

In premenopausal women with HSDD it increases sexual desire and reduces the distress tied to low desire ^[3]. The mechanism is central, not vascular: a randomised crossover fMRI study found MC4R agonism raised desire for up to 24 hours and altered how the brain processed erotic stimuli, consistent with a central rather than blood-flow effect ^[5].

That 'up to 24 hours despite a ~2.7-hour plasma half-life' gap is the tell that it changes processing rather than circulation ^[5][6]. The evidence is densest here, in the approved population, which is exactly why the approval is drawn here and nowhere else. A patient-experience analysis described how treated women perceived the benefit and tolerability in practice ^[7], and a 2025 abstract reported positive effects on arousal and orgasm beyond the desire endpoints ^[11]. None of that widens the approval — postmenopausal women remain outside it, and so does every off-label use ^[6].

Does PT-141 work?

In the approved population, yes — modestly. Across the two Phase 3 RECONNECT trials, integrated FSFI-desire improved +0.35 and FSDS-DAO item 13 (distress about low desire) fell -0.33 versus placebo, both at P<.001, and a 52-week extension sustained the desire improvement ^[3][4].

Now the honest qualifier, hung on the same wall: independent re-analyses argued those effects are small and questioned their clinical meaningfulness ^[8][9]. So the accurate answer is 'it works, and the effect is modest, and serious researchers disagree about how meaningful modest is' — which is a more useful sentence than either the hype or the dismissal.

Doses studied in women (HSDD)

Reported as label and trial findings, never as a protocol to follow. For the approved HSDD indication, the US label specifies bremelanotide 1.75 mg subcutaneously, as needed, at least 45 minutes before anticipated sexual activity, with no more than one dose per 24 hours and no more than 8 doses per month ^[6]. Phase 2 dose-finding in women studied 0.75, 1.25, and 1.75 mg before the 1.75 mg dose was carried forward ^[6].

What is the PT-141 dosage for women?

The approved label figure is 1.75 mg subcutaneously, as-needed, at least 45 minutes ahead, capped at one dose per 24 hours and 8 per month ^[6]. That is the studied and labelled figure reported as a finding — this site recommends no dose for any individual, and the research-chemical form is for laboratory use only ^[6].

How does PT-141 compare to flibanserin and testosterone for women?

Three options, three different shapes. Bremelanotide is dosed as-needed by subcutaneous injection and acts on central melanocortin receptors. Flibanserin (the other approved HSDD medication) is a daily oral serotonergic drug — a different mechanism, a different schedule, a different side-effect profile. Testosterone is used off-label for female sexual dysfunction ^[6].

A 2025 conference abstract presented a comparative analysis of flibanserin, bremelanotide, and testosterone therapy for female sexual dysfunction, contrasting their effect profiles ^[15]. The takeaway is not a winner but a fit question: as-needed injection acting on desire wiring versus a daily oral drug versus an off-label hormone, each with its own evidence and its own cost.